-
Konruns’ KC1036 Advances to Phase II Study for Lung Adenocarcinoma
•
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a Phase II clinical study of its Category 1 chemical drug KC1036. The study will assess the efficacy and safety of KC1036 in combination with docetaxel for the treatment of…
-
Harbour BioMed’s HBM1020 Receives FDA Approval for US Phase I Study
•
Harbour BioMed (HKG: 2142), a global biotech company operating in the Netherlands, the United States, and China, has announced receiving approval from the US Food and Drug Administration (FDA) to conduct an open-label, multi-center Phase I study of its monoclonal antibody (mAb) HBM1020. The study will assess the safety, tolerability,…
-
Porton Pharma Solutions to Invest EUR 50 Million in Slovenia Bio-Industry Park
•
China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions is set to establish a bio-industry park in Slovenia, marking a significant expansion of its presence in the European market. The project will involve an investment of EUR 50 million (USD 54.2 million) and will include the construction of an…
-
ClouDr Partners with Shaanxi Pharmaceutical Firms for Integrated Healthcare Solutions
•
Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), better known as “ClouDr,” has announced a strategic partnership with compatriot firms Shaanxi Pharmaceutical Holding Group Co., Ltd and Shaanxi Pharmaceutical Holding Pai Ang. The collaboration aims to leverage the respective resources and expertise of the three companies to enhance drug…
-
Syneos Health Partners with Fosun Pharma to Commercialize Serplulimab in US
•
US-based Syneos Health (Nasdaq: SYNH) has revealed a strategic partnership with Fosun Pharma USA Inc., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196), focused on the anti-programmed death-1 (PD-1) inhibitor serplulimab. Syneos will provide full commercial support in the United States for serplulimab’s development as…
-
Sanofi’s iGlarLixi Approved in China for Type 2 Diabetes Management
•
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that the National Medical Products Administration (NMPA) has approved its iGlarLixi (insulin glargine, lixisenatide) for use in adult patients with type 2 diabetes who have poor blood glucose control. This approval marks a significant step in expanding treatment options for patients struggling…
-
Roche’s Polivy Approved by China’s NMPA for Lymphoma Treatment
•
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that the National Medical Products Administration (NMPA) has approved its antibody-drug conjugate (ADC) Polivy (polatuzumab vedotin for injection). Polivy is the world’s first ADC targeting CD79b and is designed for use as a first-line treatment for diffuse large B-cell lymphoma…
-
Med Vision Secures A+ Round Financing to Accelerate Digital Therapy Commercialization
•
Hangzhou-based Med Vision Technology Co., Ltd. has successfully completed an A+ round financing, raising several tens of millions of RMB. This round was led by Hangzhou Lingxin, with existing shareholder Mifang Health Fund participating. With this financing, Med Vision has cumulatively raised over 100 million RMB in its Series A…
-
MSD China to Take Legal Action Against Market Infringement of Molnupiravir
•
Merck Sharp & Dohme (MSD, NYSE: MRK)’s China unit has issued a WeChat notification vowing to take necessary legal actions against certain unnamed drug companies accused of market infringement related to molnupiravir, the oral COVID-19 therapy. The notice states that some manufacturers are falsely claiming authorization from MSD to distribute…
-
Med Vision Secures Series A+ Funding to Expand Digital Therapy Portfolio
•
Med Vision, a Hangzhou-based digital therapy specialist, has reportedly raised “tens of millions” of renminbi in a Series A+ financing round. The funding was led by Hangzhou Lingxin Enterprise Management Partnership, with a contribution from existing investor Med-Fine Capital. The proceeds will be used to accelerate the commercialization of multiple…
-
Kexing Pharmaceutical Initiates Phase I Trial for IFN-Alpha-1b Inhalation Solution
•
China-based Kexing Pharmaceutical (SHA: 688136) has announced the enrollment of the first subject and dosing in a Phase I clinical study for its interferon-alfa-1b (IFN-alpha-1b) solution for inhalation. The drug will be assessed for treating lower respiratory tract infections caused by respiratory syncytial virus (RSV) in children, including conditions such…
-
Bioantibody Bio Raises RMB 100 Million in Series A Funding Round
•
Bioantibody Biotechnology Co., Ltd, a Nanjing-based in vitro diagnostics (IVD) and biologic company, has reportedly raised close to RMB 100 million (USD 14.8 million) in a Series A financing round. The funding was led by FangFund, with contributions from Nanjing New Industry Investment Capital, Guoqian Venture Investment Management, and Bondshine…
-
Meihua Partners with Getein Biotech to Manufacture COVID-19 Antigen Tests
•
China-based Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA) has announced a strategic partnership with compatriot firm Getein Biotech Inc. (SHA: 603387) to manufacture and market COVID-19 antigen tests and other in vitro diagnostics (IVD) products. The collaboration aims to enhance the availability and accessibility of diagnostic tools in response…
-
CSPC’s Cleviprex Approved for Clinical Study by China’s NMPA
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its pipeline drug candidate cleviprex. The company’s first nanoemulsion, cleviprex, is a dihydropyridine calcium channel blocker being developed to treat hypertension when oral antihypertensive drugs are…
-
Takeda’s Mobocertinib Approved in China for EGFR Exon20ins NSCLC
•
Japan-based Takeda Pharmaceutical Co., Ltd’s (TYO: 4502) China unit has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its lung cancer therapy mobocertinib. The drug is indicated for use in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed during…
-
MediTrust Health Secures Series C+ Funding with HSBC as Strategic Investor
•
MediTrust Health, the insurance, financing, and direct-to-patient pharmacy subsidiary of China-based Shanghai Pharmaceuticals Holding Co., Ltd, has raised an undisclosed amount in a Series C+ financing round. HSBC joined as a strategic investor, alongside other strategic shareholders including SPH, China Life Reinsurance Co., Ltd, and Shanghai Healthcare Capital (SHC). Focus…
-
Kelun-Biotech’s SKB264 Approved for Phase II Study in EGFR-Mutant NSCLC
•
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a Phase II clinical study for its drug candidate SKB264. The antibody-drug conjugate (ADC) targets trophoblast cell-surface antigen 2 (TROP2) and will be evaluated in combination with AstraZeneca’s (AZ, NASDAQ: AZN)…
-
BeiGene Outlines Global R&D Strategy at J.P. Morgan Healthcare Summit
•
China-based biotech BeiGene (Nasdaq: BGNE, HKG: 6160) provided an update on its company strategy and R&D plans at this week’s J.P. Morgan Healthcare Summit in San Francisco. BeiGene CEO John Oyler presented the firm’s globally disruptive R&D model, which includes in-house discovery capabilities and new treatment modalities set to drive…
-
Evopoint Biosciences Licenses SOS1 Inhibitor to METiS Therapeutics
•
China-based Evopoint Biosciences has announced a global licensing agreement with US firm METiS Therapeutics Inc., granting METiS exclusive global development and commercialization rights to Evopoint’s SOS1 inhibitor. Under the agreement, METiS Therapeutics will pay Evopoint “hundreds of millions” of US dollars in total upfront payment and milestone payments, along with…
-
Pfizer’s Nurtec ODT Launches in China via Hainan’s Bo’Ao Lecheng Zone
•
US-based Pfizer’s (NYSE: PFE) Nurtec ODT (rimegepant), the world’s first calcitonin gene-related peptide (CGRP) receptor antagonist in rapidly dissolving oral disintegrating tablet form, has become available to patients in China via the Bo’Ao Lecheng Medical Tourism Pilot Zone in Hainan from January 1. The drug is being launched in Hainan…
